vs
Health Catalyst, Inc.（HCAT）与CarParts.com, Inc.（PRTS）财务数据对比。点击上方公司名可切换其他公司
CarParts.com, Inc.的季度营收约是Health Catalyst, Inc.的1.6倍（$120.4M vs $74.7M），CarParts.com, Inc.净利率更高（-9.6% vs -121.9%，领先112.3%），Health Catalyst, Inc.同比增速更快（-6.2% vs -9.8%），过去两年Health Catalyst, Inc.的营收复合增速更高（-0.0% vs -8.6%）
Catalyst制药公司是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于开发罕见病治疗药物。其开发的阿米夫斯汀磷酸盐商品名为Firdapse，原本已获FDA批准用于成人兰伯特-伊顿肌无力综合征（LEMS）的治疗，2018年11月又获批可用于6岁及以上儿童LEMS患者。
GPC是一家总部位于美国佐治亚州亚特兰大的汽车与工业零部件分销商，1928年由弗雷泽兄弟创立，目前拥有约六万名员工。除美国本土市场外，公司业务还覆盖澳大拉西亚、比利时、加拿大、法国、德国、墨西哥、荷兰、波兰及英国，旗下拥有知名汽车零部件零售商NAPA Auto Parts和工业零部件分销商Motion。
HCAT vs PRTS — 直观对比
营收规模更大
PRTS
是对方的1.6倍
$74.7M
营收增速更快
HCAT
高出3.6%
-9.8%
净利率更高
PRTS
高出112.3%
-121.9%
两年增速更快
HCAT
近两年复合增速
-8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $74.7M | $120.4M |
| 净利润 | $-91.0M | $-11.6M |
| 毛利率 | — | 33.2% |
| 营业利润率 | -115.3% | — |
| 净利率 | -121.9% | -9.6% |
| 营收同比 | -6.2% | -9.8% |
| 净利润同比 | -340.3% | 25.0% |
| 每股收益（稀释后） | $-1.29 | $-0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCATPRTS
| Q4 25 | $74.7M | $120.4M | ||
| Q3 25 | $76.3M | $127.8M | ||
| Q2 25 | $80.7M | $151.9M | ||
| Q1 25 | $79.4M | $147.4M | ||
| Q4 24 | $79.6M | $133.5M | ||
| Q3 24 | $76.4M | $144.8M | ||
| Q2 24 | $75.9M | $144.3M | ||
| Q1 24 | $74.7M | — |
净利润HCATPRTS
| Q4 25 | $-91.0M | $-11.6M | ||
| Q3 25 | $-22.2M | $-10.9M | ||
| Q2 25 | $-41.0M | $-12.7M | ||
| Q1 25 | $-23.7M | $-15.3M | ||
| Q4 24 | $-20.7M | $-15.4M | ||
| Q3 24 | $-14.7M | $-10.0M | ||
| Q2 24 | $-13.5M | $-8.7M | ||
| Q1 24 | $-20.6M | — |
毛利率HCATPRTS
| Q4 25 | — | 33.2% | ||
| Q3 25 | 52.6% | 33.1% | ||
| Q2 25 | — | 32.8% | ||
| Q1 25 | — | 32.1% | ||
| Q4 24 | — | 32.5% | ||
| Q3 24 | 47.5% | 35.2% | ||
| Q2 24 | — | 33.5% | ||
| Q1 24 | — | — |
营业利润率HCATPRTS
| Q4 25 | -115.3% | — | ||
| Q3 25 | -22.9% | -7.9% | ||
| Q2 25 | -46.0% | -8.2% | ||
| Q1 25 | -25.4% | -10.3% | ||
| Q4 24 | -22.0% | -11.6% | ||
| Q3 24 | -17.9% | -6.9% | ||
| Q2 24 | -20.8% | -6.0% | ||
| Q1 24 | -30.5% | — |
净利率HCATPRTS
| Q4 25 | -121.9% | -9.6% | ||
| Q3 25 | -29.1% | -8.5% | ||
| Q2 25 | -50.8% | -8.4% | ||
| Q1 25 | -29.9% | -10.4% | ||
| Q4 24 | -26.0% | -11.5% | ||
| Q3 24 | -19.3% | -6.9% | ||
| Q2 24 | -17.8% | -6.0% | ||
| Q1 24 | -27.6% | — |
每股收益（稀释后）HCATPRTS
| Q4 25 | $-1.29 | $-0.82 | ||
| Q3 25 | $-0.32 | $-0.19 | ||
| Q2 25 | $-0.59 | $-0.23 | ||
| Q1 25 | $-0.35 | $-0.27 | ||
| Q4 24 | $-0.33 | $-0.28 | ||
| Q3 24 | $-0.24 | $-0.17 | ||
| Q2 24 | $-0.23 | $-0.15 | ||
| Q1 24 | $-0.35 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $95.7M | $25.8M |
| 总债务越低越好 | $153.3M | — |
| 股东权益账面价值 | $245.8M | $53.5M |
| 总资产 | $502.6M | $184.9M |
| 负债/权益比越低杠杆越低 | 0.62× | — |
8季度趋势，按日历期对齐
现金及短期投资HCATPRTS
| Q4 25 | $95.7M | $25.8M | ||
| Q3 25 | $91.5M | — | ||
| Q2 25 | $97.3M | — | ||
| Q1 25 | $342.0M | — | ||
| Q4 24 | $392.0M | — | ||
| Q3 24 | $387.3M | — | ||
| Q2 24 | $308.3M | — | ||
| Q1 24 | $327.8M | — |
总债务HCATPRTS
| Q4 25 | $153.3M | — | ||
| Q3 25 | $153.1M | — | ||
| Q2 25 | $153.0M | — | ||
| Q1 25 | $382.9M | — | ||
| Q4 24 | $382.4M | — | ||
| Q3 24 | $345.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HCATPRTS
| Q4 25 | $245.8M | $53.5M | ||
| Q3 25 | $331.9M | $64.2M | ||
| Q2 25 | $347.5M | $62.4M | ||
| Q1 25 | $376.8M | $72.8M | ||
| Q4 24 | $365.2M | $85.2M | ||
| Q3 24 | $355.0M | $97.2M | ||
| Q2 24 | $357.0M | $103.9M | ||
| Q1 24 | $357.2M | — |
总资产HCATPRTS
| Q4 25 | $502.6M | $184.9M | ||
| Q3 25 | $587.1M | $200.3M | ||
| Q2 25 | $616.2M | $189.6M | ||
| Q1 25 | $891.5M | $216.5M | ||
| Q4 24 | $858.9M | $210.6M | ||
| Q3 24 | $813.0M | $227.6M | ||
| Q2 24 | $691.7M | $238.0M | ||
| Q1 24 | $695.1M | — |
负债/权益比HCATPRTS
| Q4 25 | 0.62× | — | ||
| Q3 25 | 0.46× | — | ||
| Q2 25 | 0.44× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | 1.05× | — | ||
| Q3 24 | 0.97× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | — |
| 自由现金流经营现金流 - 资本支出 | $9.6M | — |
| 自由现金流率自由现金流/营收 | 12.9% | — |
| 资本支出强度资本支出/营收 | 0.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-697.0K | — |
8季度趋势，按日历期对齐
经营现金流HCATPRTS
| Q4 25 | $9.9M | — | ||
| Q3 25 | $-464.0K | $-6.4M | ||
| Q2 25 | $-9.0M | $-25.6M | ||
| Q1 25 | $280.0K | $5.5M | ||
| Q4 24 | $-3.5M | $1.8M | ||
| Q3 24 | $6.2M | $8.5M | ||
| Q2 24 | $1.6M | $-3.6M | ||
| Q1 24 | $10.3M | — |
自由现金流HCATPRTS
| Q4 25 | $9.6M | — | ||
| Q3 25 | $-719.0K | $-8.3M | ||
| Q2 25 | $-9.2M | $-27.9M | ||
| Q1 25 | $-390.0K | $3.4M | ||
| Q4 24 | $-3.9M | $-631.0K | ||
| Q3 24 | $5.5M | $4.9M | ||
| Q2 24 | $1.3M | $-10.8M | ||
| Q1 24 | $10.1M | — |
自由现金流率HCATPRTS
| Q4 25 | 12.9% | — | ||
| Q3 25 | -0.9% | -6.5% | ||
| Q2 25 | -11.4% | -18.3% | ||
| Q1 25 | -0.5% | 2.3% | ||
| Q4 24 | -4.9% | -0.5% | ||
| Q3 24 | 7.2% | 3.4% | ||
| Q2 24 | 1.7% | -7.5% | ||
| Q1 24 | 13.5% | — |
资本支出强度HCATPRTS
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.3% | 1.5% | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.8% | 1.4% | ||
| Q4 24 | 0.5% | 1.8% | ||
| Q3 24 | 0.9% | 2.5% | ||
| Q2 24 | 0.4% | 4.9% | ||
| Q1 24 | 0.3% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HCAT
| Recurring Technology | $51.9M | 69% |
| Professional Services | $22.8M | 31% |
PRTS
暂无分部数据
